Silence Therapeutics priced an upsized public offering expected to raise about $175 million, with proceeds earmarked for its short interfering RNA (siRNA) programs including divesiran. The funding follows a “best-case” Phase 2 outcome for divesiran in a rare leukemia indication, positioning the program for continued clinical development. The offering adds capital after the company had proposed raising roughly $150 million, reflecting investor demand. For biotech, the update highlights how Phase 2 risk reduction can quickly translate into market access for cash-intensive nucleic-acid platforms. If realized, the financing expands Silence’s ability to fund manufacturing, trial execution, and regulatory preparation across its siRNA pipeline.